

## United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	. •	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/910,358		07/19/2001	Wenyuan Shi	2101363-991200	2383
29585	7590	02/10/2004		EXAMINER	
		ARE & FREIDENRI	FORD, VANESSA L		
153 TOWNSEND SUITE 800 SAN FRANCISCO, CA 94107			ART UNIT	PAPER NUMBER	
			1645		
				DATE MAILED: 02/10/2004	

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)					
	09/910,358	SHI					
Office Action Summary	Examiner	Art Unit					
	Vanessa L. Ford	1645					
Th MAILING DATE of this communication appears on the cover she to with the correspondence address Period for Reply							
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.  - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.  - If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.  - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.  - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).  - Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).  Status							
1) Responsive to communication(s) filed on 19 J	<u>uly 2001</u> .						
2a) ☐ This action is <b>FINAL</b> . 2b) ☐ Thi	is action is non-final.						
3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.							
Disposition of Claims							
4)⊠ Claim(s) <u>1-22</u> is/are pending in the application							
4a) Of the above claim(s) is/are withdrawn from consideration.							
5) Claim(s) is/are allowed.							
6) Claim(s) is/are rejected.							
7) Claim(s) is/are objected to.							
8) Claim(s) 1-22 are subject to restriction and/or election requirement.							
Application Papers  OND The specification is objected to by the Examiner							
9) The specification is objected to by the Examiner.							
10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner.  Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).							
11) The proposed drawing correction filed on is: a) approved b) disapproved by the Examiner.							
If approved, corrected drawings are required in reply to this Office action.							
12) ☐ The oath or declaration is objected to by the Examiner.							
Priority under 35 U.S.C. §§ 119 and 120							
13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).							
a) ☐ All b) ☐ Some * c) ☐ None of:							
1. Certified copies of the priority documents	s have been received.	-					
2. Certified copies of the priority documents	s have been received in Applica	ition No					
Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).  * See the attached detailed Office action for a list of the certified copies not received.							
14) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).							
a) ☐ The translation of the foreign language provisional application has been received.							
15) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.							
Attachment(s)							
Notice of References Cited (PTO-892)     Notice of Draftsperson's Patent Drawing Review (PTO-948)     Information Disclosure Statement(s) (PTO-1449) Paper No(s)	5) Notice of Informa	ary (PTO-413) Paper No(s) Il Patent Application (PTO-152)					

Application/Control Number: 09/910,358

Art Unit: 1645

## **Election/Restriction**

- 1. Restriction to one of the following inventions is required under 35 U.S.C. 121:
  - Group I Claims 1-9 and 22 are drawn to a fusion protein, classified in class 435, subclass, 69.7. Further species election required.
  - Group II Claims 10-21 is drawn to a method of treating microbial infections, classified in class 424, subclass, 184.1. Further species election required.
- 2. Groups I and II are product and process of using. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a material different process of using that product (MPEP 806.05(h)). In the instant case, fusion protein can be used to make antibodies.
- 3. In the event applicant elects Group I, claims 1-9 and 22 applicant is required to elect a single antimicrobial peptide to be examined. Claims 1-9 and 22 recite two distinct antimicrobial peptides, based on structural differences, comprising:

  Species A, drawn to histatin 5, and corresponding sequences (SEQ ID NO: 1 (nucleic acid encoding peptide) and SEQ ID NO:4 (amino acid of the peptide)).

  Species B, drawn to dhvar1, and corresponding sequences (SEQ ID NO: 5 (nucleic acid encoding peptide) and SEQ ID NO:8 (amino acid of the peptide)).

Application/Control Number: 09/910,358

Art Unit: 1645

4. In the event applicant elects Group II, claims 10-21 applicant is required to elect

Page 3

a single antimicrobial peptide to be examined. Claims 10-21 recite two distinct

antimicrobial peptides, based on structural differences, comprising:

Species A, drawn to histatin 5, and corresponding sequences (SEQ ID NO: 1 (nucleic

acid encoding peptide) and SEQ ID NO:4 (amino acid of the peptide)).

Species B, drawn to dhvar1, and corresponding sequences (SEQ ID NO: 5 (nucleic

acid encoding peptide) and SEQ ID NO:8 (amino acid of the peptide)).

5. Because these inventions are distinct for the reasons given and have acquired a

separate status in the art because of their recognized divergent subject matter as

shown by their different classification, restriction for examination purposes as indicated

is proper. Moreover, in the absence of restriction it would place an undue search and

examination burden on the examiner.

6. Applicant is advised that the reply to this requirement to be complete must

include an election of invention to be examined even though the requirement be

traversed (37 CFR 1.143).

Application/Control Number: 09/910,358

Art Unit: 1645

Page 4

7. Applicant is reminded that upon that upon cancellation of claims to a non-elected

invention, the inventorship must be amended in compliance with 37 C.F.R. 1.48(b) if

one or more of the currently named inventors is no longer an inventor of at least one

claim remaining in the application. Any amendment of inventorship must be

accompanied by a diligently-filed petition under 37 C.F.R. 1.48(b) and by the fee

required under 37 C.F.R. 1.17(h).

8. Any inquiry of the general nature or relating to the status of this general application should be directed to the Group receptionist whose telephone number is

(703) 308-0196.

Papers relating to this application may be submitted to Technology Center 1600, Group 1640 by facsimile transmission. The faxing of such papers must conform with the notice published in the Office Gazette, 1096 OG 30 (November 15, 1989). Should applicant wish to FAX a response, the current FAX number for the Group 1600 is (703) 308-4242.

Any inquiry concerning this communication from the examiner should be directed to Vanessa L. Ford, whose telephone number is (571) 272-0857. The examiner can normally be reached on Monday – Friday from 7:30 AM to 4:00 PM. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Lynette Smith, can be reached at (571) 272–0864.

Vanessa Ľ. Ford

**Biotechnology Patent Examiner** 

February 5, 2004

LYNETTE R. F. SMITH
SUPERVISORY PATENT EXAMINER
TECHNOLOGY CENTER 1600